MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (finance)
- RELIGARE ENT.
RELIGARE ENT. Share Price 
(RELIG)
Here is the latest stock price and chart of Religare Enterprises. For more details, see the Religare Enterprises company fact sheet and quarterly results. For a sector overview, read our finance sector report.
| Live BSE Quotes | Mar 20, 2019 10:47:00 AM | ||
|---|---|---|---|
| Price (Rs)30.60 | Open (Rs) 30.80 | High (Rs) 30.85 | Low (Rs) 30.60 |
| % Change-1.13 | Volume 4,110 | Value (Rs) 125,766 | 52-Week H/L 61.65 / 17.05 |
| Live NSE Quotes | Mar 20, 2019 10:49:23 AM | ||
|---|---|---|---|
| Price (Rs)30.65 | Open (Rs) 31.00 | High (Rs) 31.00 | Low (Rs) 30.50 |
| % Change-1.61 | Volume 21,383 | Value (Rs) 656,886 | 52-Week H/L 61.65 / 16.90 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* -5.86 | P/E Ratio (x) NM | Market Cap (Rs m) 5,456.90 | P/BV (x) 0.32 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
RELIGARE ENT. Share Price Today:
RELIGARE ENT. share price is down 1.1% to Rs 30.6 on the BSE. On the NSE, the RELIGARE ENT. share price is down 1.6% to Rs 30.7. The total volume of shares traded is 0.0 m.
Overall, the benchmark S&P BSE SENSEX is trading at 38,444.7 (up 0.2%).
Over the last 30 days, the RELIGARE ENT. share price is up 53.0%. And over the last one year, RELIGARE ENT. share price is down 45.3%.
|
| |
Today's Market
Indian Share Markets Open Flat; Energy and Automobile Stocks Lag(09:30 am)
Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.3% while the Hang Seng is up 0.1%.
Related Views On News
RELIGARE ENT. Announces Quarterly Results (3QFY19); Net Profit Up 75.2% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, RELIGARE ENT. has posted a net profit of Rs 103 m (up 75.2% YoY). Sales on the other hand came in at Rs 8 m (down 90.1% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.
RELIGARE ENT. 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of RELIGARE ENT. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of RELIGARE ENT.. Also includes updates on the valuation of RELIGARE ENT..
RELIGARE ENT. Announces Quarterly Results (2QFY19); Net Profit Up 57.9% (Quarterly Result Update)
Nov 29, 2018 | Updated on Nov 29, 2018For the quarter ended September 2018, RELIGARE ENT. has posted a net profit of Rs 128 m (up 57.9% YoY). Sales on the other hand came in at Rs 13 m (down 50.7% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.
CreditAccess Grameen IPO: Should You Apply to this Interesting Microfinance Play? (IPO)
Aug 7, 2018Should you apply to the IPO of CreditAccess Grameen Ltd?
HDFC AMC IPO: Do Valuations Leave Enough on Table for Investors? (IPO)
Jul 20, 2018Should you subscribe to the IPO of HDFC AMC Ltd?
More Views on NewsMost Popular
Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)
Mar 8, 2019History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?
Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)
Mar 7, 2019Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...
The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Mar 7, 2019India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?
Elections Don't Matter!(The Honest Truth)
Mar 13, 2019Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.
Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)
Mar 13, 2019The elements that fueled profit growth for these two companies led to a surge in their stock prices.
MoreTRACK RELIGARE ENT.
- Track your investment in RELIGARE ENT. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON RELIGARE ENT.
RELIGARE ENT. - COX & KINGS COMPARISON
COMPARE RELIGARE ENT. WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.